Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Blood (2024) 144 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2024-200038

Published: 2024

Journal Articles

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Blood (2024) 144 (Supplement 1): 892.

https://doi.org/10.1182/blood-2024-204700

Published: 2024

Journal Articles

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

Blood (2024) 143 (8): 734–737.

https://doi.org/10.1182/blood.2023022937

Published: 2024

Journal Articles

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs

Blood (2022) 140 (Supplement 1): 12618–12620.

https://doi.org/10.1182/blood-2022-166337

Published: 2022

Journal Articles

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Murielle Roussel, Michelle Pirotte, Ornella Rizzo, Kentin Queru, Thomas Chalopin, Olivier Decaux, Estelle Desport, Frank Bridoux, Arnaud Jaccard

Blood (2022) 140 (Supplement 1): 10086–10087.

https://doi.org/10.1182/blood-2022-166224

Published: 2022

Journal Articles

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Blood (2022) 140 (Supplement 1): 10068–10070.

https://doi.org/10.1182/blood-2022-162754

Published: 2022

Journal Articles

Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal

Christophe Sirac, Arnaud Jaccard, Roussine Codo, Sebastien Bender, Gemma Martinez-Rivas, Frank Bridoux, Gregory D Bell, Spencer Guthrie, Suganya Selvarajah, Stephen J. Kennel, Angela Williams, James S. Foster, Jonathan S. Wall

Blood (2021) 138 (Supplement 1): 1207.

https://doi.org/10.1182/blood-2021-151908

Published: 2021

Journal Articles

A Transgenic Mouse Model of Cardiac AL Amyloidosis

Gemma Martinez-Rivas, Maria Ayala, Sebastien Bender, Murielle Roussel, Arnaud Jaccard, Frank Bridoux, Christophe Sirac

Blood (2021) 138 (Supplement 1): 1592.

https://doi.org/10.1182/blood-2021-146782

Published: 2021

Journal Articles

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Blood (2021) 138 (Supplement 1): 153.

https://doi.org/10.1182/blood-2021-152675

Published: 2021

Journal Articles

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Paolo Milani, MDPhD, Nelson Leung, MD, Efstathios Kastritis, MD, Stefan Schönland, MD, Ute Hegenbart, MD, Frank Bridoux, MD, Florent Joly, MD, Sascha A Tuchman, MD, Victor Jimenez-Zepeda, MD, Sriram Ravichandran, MBBS, MRCP, FRCPath, Holly Lee, MD, Tamara Berno, MD, Giampaolo Merlini, MD, Giovanni Palladini, MD PhD, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-141662

Published: 2020

Journal Articles

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Giovanni Palladini, MD PhD, Stefan Schönland, MD, Giampaolo Merlini, MD, Paolo Milani, MDPhD, Arnaud Jaccard, MD PhD, Frank Bridoux, MD PhD, Wilfried Roeloffzen, MD PhD, M. Teresa Cibeira, MD PhD, Hermine Agis, MD, Monique C. Minnema, MD PhD, Rui Bergantim, MD, Roman Hajek, MD PhD, Cristina João, MD PhD MSc, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Pieter Sonneveld, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140708

Published: 2020

Journal Articles

Immunoglobulin light-chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease

Blood (2020) 136 (14): 1645–1656.

https://doi.org/10.1182/blood.2020005980

Published: 2020

Includes: Supplemental data

Journal Articles

Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

Blood (2020) 135 (21): 1833–1846.

https://doi.org/10.1182/blood.2019003807

Published: 2020

Includes: Supplemental data

Journal Articles

Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome

Sébastien Bender, Vincent Javaugue, Alexis Saintamand, Maria Victoria Ayala, Mehdi Alizadeh, Matthieu Filloux, Virginie Pascal, Nathalie Gachard, David Lavergne, Fabienne Auroy, Michel Cogné, Frank Bridoux, Christophe Sirac, Arnaud Jaccard

Blood (2020) 135 (20): 1750–1758.

https://doi.org/10.1182/blood.2019004197

Published: 2020

Includes: Supplemental data

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study

Florent Joly, Camille Cohen, Vincent Javaugue, Sébastien Bender, Mohamed Belmouaz, Bertrand Arnulf, Bertrand Knebelmann, Mathilde Nouvier, Vincent Audard, François Provot, Viviane Gnemmi, Dominique Nochy, Jean Michel Goujon, Arnaud Jaccard, Guy Touchard, Jean Paul Fermand, Christophe Sirac, Frank Bridoux

Blood (2019) 133 (6): 576–587.

https://doi.org/10.1182/blood-2018-09-872028

Published: 2019

Includes: Supplemental data

Journal Articles

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications

Jean-Paul Fermand, Frank Bridoux, Angela Dispenzieri, Arnaud Jaccard, Robert A. Kyle, Nelson Leung, Giampaolo Merlini

Blood (2018) 132 (14): 1478–1485.

https://doi.org/10.1182/blood-2018-04-839480

Published: 2018

Journal Articles

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants

Cyrille Garnier, Fatma Briki, Brigitte Nedelec, Patrick Le Pogamp, Ahmet Dogan, Nathalie Rioux-Leclercq, Renan Goude, Caroline Beugnet, Laurent Martin, Marc Delpech, Frank Bridoux, Gilles Grateau, Jean Doucet, Philippe Derreumaux, Sophie Valleix

Blood (2017) 130 (25): 2799–2807.

https://doi.org/10.1182/blood-2017-07-796185

Published: 2017

Journal Articles

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Murielle Roussel, MD, Anne-Marie Stoppa, MD, Aurore Perrot, MD, Lionel Karlin, MD, Bertrand Arnulf, MD PhD, Margaret Macro, MD, Antoine Huart, MD, Laurent Frenzel, MD PhD, Pierre Morel, MD, Eileen Boyle, MD, Veronique Dorvaux, MD, Giampaolo Merlini, MD, Giovanni Palladini, MDPhD, David Lavergne, PhD, Frank Bridoux, MD PhD, Arnaud Jaccard

Blood (2017) 130 (Supplement 1): 508.

https://doi.org/10.1182/blood.V130.Suppl_1.508.508

Published: 2017

Journal Articles

Prognostic Significance of Plasmablastic Plasma Cells in the Era of Novel Agents in Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1877.

https://doi.org/10.1182/blood.V130.Suppl_1.1877.1877

Published: 2017

NARROW

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series

A Phase 2 Single-Arm Study to Evaluate the Efficacy of Isatuximab, Pomalidomide and Low-Dose Dexamethasone, in Patients with AL Amyloidosis Not in VGPR or Better after Any Previous Therapy (IsAMYP)

Venetoclax-Targeted Therapy in t(11;14) AL Amyloidosis Patients after Frontline Daratumumab and Cybord: A Retrospective Analysis from the French Amyloidosis Network

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Pre-Clinical Characterization of a Novel Fusion Protein (AT-03), with Pan-Amyloid Binding and Removal

A Transgenic Mouse Model of Cardiac AL Amyloidosis

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Immunoglobulin light-chain toxicity in a mouse model of monoclonal immunoglobulin light-chain deposition disease

Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications

VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants

A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Prognostic Significance of Plasmablastic Plasma Cells in the Era of Novel Agents in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only